Cellectis therapeutics hires Dr Andrew Scharenberg as CSO
This article was originally published in Scrip
Executive Summary
Cellectis therapeutics has appointed Dr Andrew Scharenberg chief scientific officer. Dr Scharenberg is an attending physician in immunology at Seattle Children's Hospital, a principal investigator and co-director of the Northwest Genome Engineering Consortium, and co-founder and a member of the board of directors of Pregenen, a biotechnology spin-off from the NGEC and a strategic partner of Cellectis.